Araştırma Makalesi
BibTex RIS Kaynak Göster

Yıl 2020, Cilt: 42 Sayı: 3, 301 - 310, 27.10.2020

Pınar Gökçen , Ender Kurt

https://doi.org/10.7197/cmj.vi.742816

Öz

Kaynakça

  • 1. Buckner JC, Brown PD, O'Neill BP, et al. Central nervous system tumors. Mayo Clin Proc 2007; 82: 1271-86.
  • 2. Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008 (March 23, 2012 Revision) Hinsdale, IL: CBTRUS; 2012
  • 3. Duffau L, Capelle L. Preferential brain locations of low-grade gliomas. Cancer 2004; 100: 2622–6.
  • 4. Henson JW, Gaviani P, Gonzalez RG. MRI in treatment of adult gliomas. Lancet Oncol 2005; 6: 167-75.
  • 5. Schiff D, Brown PD, Giannini C. Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 2007; 69: 1366–73.
  • 6. Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973–2001. Cancer 2006; 106: 1358–63.
  • 7. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975- 2012. Available at: http://seer.cancer.gov/csr/1975_2012/.
  • 8. Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004; 22: 3133-8.
  • 9. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003; 21: 646-51.
  • 10. Murphy PS Viviers L, Abson C, et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 2004; 90: 781-6.
  • 11. Hirano H, Asakura T, Yokoyama S, et al. The prognostic factors in astrocytic tumors: analysis by the Kaplan-Meier method and the Weibull log-linear model. No Shinkei Geka 1996; 24(9): 809-15.
  • 12. T. Gorlia, R. Stupp, E. A. Eisenhauer, R. O. Mirimanoff, M. J. Van Den Bent, K. Belanger, D. Lacombe, A. Allgeier, European Organisation for Research and Treatment of Cancer (EORTC) Brain And Radiotherapy Groups, National Cancer Institute of Canada (NCIC) Clinical Trials Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM) Group40th ASCO Annual Meeting. New Orleans, LA. June 5- 8, 2004. Abstract No. 9599 (Clinical Study).
  • 13. Phi JH, Chung CK. Brain tumors in the mesial temporal lobe: long-term oncological outcome. Neurosurg Focus 2009;27(2):E5.
  • 14. Reavey-Cantwell JF, Haroun RI, Zahurak M, et al. The prognostic value of tumor markers in patients wit glioblastoma multiforme: analysis of 32 patients and review of the literature. Neurooncol 2001; 55(3): 195-204.
  • 15. Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 2003; 53: 524–8.
  • 16. Packer RJ, Sutton LN, Rorke LB, Littman P, Bruce DA. Oligodendroglioma of Posterior fossa in Childhood. Cancer 1985; 56: 195-9.
  • 17. Cancer Facts and figures 2002, American Cancer Society, Surveillance Research, Atlanta, 2002.
  • 18. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic responce and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst 1998; 90: 1473-9.
  • 19. Van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003; 21: 2525–8.
  • 20. Kros JM, Hop WC, Godschalk JJ et al. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 1996; 78: 1107–13.
  • 21. Burger PC, Scheithauer B, Vogel FS. Surgical Pathology of the Nervous System and Its Converings, Fourth Edition. New York: Churchill Livingstone 2002.
  • 22. Jin Q, Zhang W, Qiu XG, et al. Gene expression profiling reveals Ki-67 associated proliferation signature in human glioblastoma. Chin Med J 2011; 124: 2584-8.
  • 23. Arshad H, Ahmad Z, Hasan SH. Gliomas: Correlation og Histologic Grade, Ki67 and p53 Expression with Patient Survival. Asian Pacific J Cancer Prev 2010; 11: 1637- 40.
  • 24. Kayaselçuk F, Zorludemir S, Gümürdühü D, Zeren H, Erman T. PCNA and Ki-67 in central nervous system tumors: correlation with the histological type and grade. Journal of Neuro-Oncology 2002; 57: 115–21.
  • 25. Kato H, Kato S, Kumabe T, et al. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 2000; 6(10): 3937-43.
  • 26. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 1997; 56: 180- 185.
  • 27. Hirose T, Ishizawa K, Shimada S. Utility of in situ demonstration of 1p loss and p53 overexpression pathologic diagnosis of oligodendroglial tumors. Neuropathology 2010; 30(6): 586- 96.
  • 28. Niranjan R, Kamat PK, Nath C, Shukla R. Evaluation of guggulipid and nimesulide on production of inflammatory mediators and GFAP expression in LPS stimulated rat astrocytoma, cell line (C6). Journal of Ethnopharmacology 2010; 127(3): 625–30.

Factors that affect survival in low grade gliomas and the prognostic significance of the Ki -67 proliferation index

Yıl 2020, Cilt: 42 Sayı: 3, 301 - 310, 27.10.2020

Pınar Gökçen , Ender Kurt

https://doi.org/10.7197/cmj.vi.742816

Öz

Objective: Low grade gliomas are a heterogeneous group of neoplasms that can progress to malignant gliomas. Various proliferation markers are researched by histopathologists at increasing rates to determine the prognostic behavior of brain tumors. In this study, we aimed to investigate the prognostic significance of the Ki-67 proliferation index in low grade gliomas. 
Method: This retrospective study included 38 cases diagnosed with low grade gliomas of WHO grades I and II according to the data retrieved from patient files. Patient characteristics such as age, gender, histology, grade and localization of tumors, treatment options, and recurrence rates were recorded. Immunohistochemical analysis was performed using Ki -67 antibodies, p53, GFAP and others, using paraffin sections. 
Results:There were 20 female (% 52.6) and 18 male (% 47.4) patients, with a mean age of 40.32 ± 9.99 years (range: 23- 63). The most common histologic type was oligodendroglioma. The progression-free survival (PFS) time was 35.93 ± 5.16 months, and the overall survival (OS) time was 110.98 ± 9.08 months. Patients with frontal tumors showed longer survival times compared to those with temporal and parietal tumors (115.25 ± 7.42 versus 47.50 ± 5.63 and 33.75 ± 8.80 months), respectively (p:0.014). The Ki-67 proliferative index and other clinicopathological characteristics were found to have no effect on PFS and OS. 
Conclusions: More comprehensive case series that will use different cut-off values are warranted to understand the effect of the Ki-67 proliferative index on the prognosis and survival in low-grade glial tumours more clearly.

Anahtar Kelimeler

glial tumors Ki-67 proliferation index

Kaynakça

  • 1. Buckner JC, Brown PD, O'Neill BP, et al. Central nervous system tumors. Mayo Clin Proc 2007; 82: 1271-86.
  • 2. Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008 (March 23, 2012 Revision) Hinsdale, IL: CBTRUS; 2012
  • 3. Duffau L, Capelle L. Preferential brain locations of low-grade gliomas. Cancer 2004; 100: 2622–6.
  • 4. Henson JW, Gaviani P, Gonzalez RG. MRI in treatment of adult gliomas. Lancet Oncol 2005; 6: 167-75.
  • 5. Schiff D, Brown PD, Giannini C. Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 2007; 69: 1366–73.
  • 6. Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973–2001. Cancer 2006; 106: 1358–63.
  • 7. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975- 2012. Available at: http://seer.cancer.gov/csr/1975_2012/.
  • 8. Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004; 22: 3133-8.
  • 9. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003; 21: 646-51.
  • 10. Murphy PS Viviers L, Abson C, et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 2004; 90: 781-6.
  • 11. Hirano H, Asakura T, Yokoyama S, et al. The prognostic factors in astrocytic tumors: analysis by the Kaplan-Meier method and the Weibull log-linear model. No Shinkei Geka 1996; 24(9): 809-15.
  • 12. T. Gorlia, R. Stupp, E. A. Eisenhauer, R. O. Mirimanoff, M. J. Van Den Bent, K. Belanger, D. Lacombe, A. Allgeier, European Organisation for Research and Treatment of Cancer (EORTC) Brain And Radiotherapy Groups, National Cancer Institute of Canada (NCIC) Clinical Trials Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM) Group40th ASCO Annual Meeting. New Orleans, LA. June 5- 8, 2004. Abstract No. 9599 (Clinical Study).
  • 13. Phi JH, Chung CK. Brain tumors in the mesial temporal lobe: long-term oncological outcome. Neurosurg Focus 2009;27(2):E5.
  • 14. Reavey-Cantwell JF, Haroun RI, Zahurak M, et al. The prognostic value of tumor markers in patients wit glioblastoma multiforme: analysis of 32 patients and review of the literature. Neurooncol 2001; 55(3): 195-204.
  • 15. Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 2003; 53: 524–8.
  • 16. Packer RJ, Sutton LN, Rorke LB, Littman P, Bruce DA. Oligodendroglioma of Posterior fossa in Childhood. Cancer 1985; 56: 195-9.
  • 17. Cancer Facts and figures 2002, American Cancer Society, Surveillance Research, Atlanta, 2002.
  • 18. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic responce and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst 1998; 90: 1473-9.
  • 19. Van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003; 21: 2525–8.
  • 20. Kros JM, Hop WC, Godschalk JJ et al. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 1996; 78: 1107–13.
  • 21. Burger PC, Scheithauer B, Vogel FS. Surgical Pathology of the Nervous System and Its Converings, Fourth Edition. New York: Churchill Livingstone 2002.
  • 22. Jin Q, Zhang W, Qiu XG, et al. Gene expression profiling reveals Ki-67 associated proliferation signature in human glioblastoma. Chin Med J 2011; 124: 2584-8.
  • 23. Arshad H, Ahmad Z, Hasan SH. Gliomas: Correlation og Histologic Grade, Ki67 and p53 Expression with Patient Survival. Asian Pacific J Cancer Prev 2010; 11: 1637- 40.
  • 24. Kayaselçuk F, Zorludemir S, Gümürdühü D, Zeren H, Erman T. PCNA and Ki-67 in central nervous system tumors: correlation with the histological type and grade. Journal of Neuro-Oncology 2002; 57: 115–21.
  • 25. Kato H, Kato S, Kumabe T, et al. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 2000; 6(10): 3937-43.
  • 26. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 1997; 56: 180- 185.
  • 27. Hirose T, Ishizawa K, Shimada S. Utility of in situ demonstration of 1p loss and p53 overexpression pathologic diagnosis of oligodendroglial tumors. Neuropathology 2010; 30(6): 586- 96.
  • 28. Niranjan R, Kamat PK, Nath C, Shukla R. Evaluation of guggulipid and nimesulide on production of inflammatory mediators and GFAP expression in LPS stimulated rat astrocytoma, cell line (C6). Journal of Ethnopharmacology 2010; 127(3): 625–30.
Toplam 28 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Medical Science Research Makaleler
Yazarlar

Pınar Gökçen 0000-0002-6742-6976

Ender Kurt 0000-0002-5446-1254

Yayımlanma Tarihi 27 Ekim 2020
Kabul Tarihi 18 Eylül 2020
Yayımlandığı Sayı Yıl 2020Cilt: 42 Sayı: 3

Kaynak Göster

AMA Gökçen P, Kurt E. Factors that affect survival in low grade gliomas and the prognostic significance of the Ki -67 proliferation index. CMJ. Ekim 2020;42(3):301-310. doi:10.7197/cmj.vi.742816